EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.

Authors: Riad Salem, Anne M. Noonan, Benjamin Spieler, Sarah B. White, Laura Kulik, Dex L. Underwood, Eric Heilbron, Binh Nguyen, Graham Wetherill, Renuka Iyer

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4221

Source: Full article

---

Abstract

TPS4221